Blueprint Medicines Announces Pricing of Initial Public Offering
A registration statement relating to these securities has been filed with and was declared effective by the
The offering will be made only by means of a prospectus. A preliminary prospectus describing the terms of the offering has been filed with the
Contact:
Investor Relations:
Beth DelGiacco
Stern Investor Relations, Inc.
212-362-1200
beth@sternir.com
Media:
Beth Keshishian
inVentiv Health PR
212-229-8417
beth.keshishian@inventivhealth.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blueprint-medicines-announces-pricing-of-initial-public-offering-300074756.html
SOURCE Blueprint Medicines